Vanguard Group’s Arcadia Biosciences RKDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $27.8K | Hold |
14,038
| – | – | ﹤0.01% | 4292 |
|
|
2025
Q3 | $48.7K | Hold |
14,038
| – | – | ﹤0.01% | 4299 |
|
|
2025
Q2 | $61.9K | Hold |
14,038
| – | – | ﹤0.01% | 4180 |
|
|
2025
Q1 | $39.9K | Hold |
14,038
| – | – | ﹤0.01% | 4207 |
|
|
2024
Q4 | $83.1K | Hold |
14,038
| – | – | ﹤0.01% | 4178 |
|
|
2024
Q3 | $39.3K | Hold |
14,038
| – | – | ﹤0.01% | 4259 |
|
|
2024
Q2 | $44.2K | Hold |
14,038
| – | – | ﹤0.01% | 4302 |
|
|
2024
Q1 | $31K | Hold |
14,038
| – | – | ﹤0.01% | 4358 |
|
|
2023
Q4 | $43.9K | Buy |
+14,038
| New | +$43.9K | ﹤0.01% | 4382 |
|
|
2023
Q1 | – | Sell |
-7,683
| Closed | -$83.3K | – | 4573 |
|
|
2022
Q4 | $83.3K | Sell |
7,683
-11,091
| -59% | -$158K | ﹤0.01% | 4409 |
|
|
2022
Q3 | $396K | Sell |
18,774
-994
| -5% | -$33.9K | ﹤0.01% | 4277 |
|
|
2022
Q2 | $790K | Hold |
19,768
| – | – | ﹤0.01% | 4161 |
|
|
2022
Q1 | $1.1M | Hold |
19,768
| – | – | ﹤0.01% | 4173 |
|
|
2021
Q4 | $821K | Sell |
19,768
-37
| -0.2% | -$2.41K | ﹤0.01% | 4314 |
|
|
2021
Q3 | $1.64M | Hold |
19,805
| – | – | ﹤0.01% | 4120 |
|
|
2021
Q2 | $2.35M | Buy |
19,805
+10,273
| +108% | +$1.12M | ﹤0.01% | 3925 |
|
|
2021
Q1 | $1.05M | Buy |
9,532
+2,932
| +44% | +$360K | ﹤0.01% | 3998 |
|
|
2020
Q4 | $667K | Buy |
6,600
+184
| +3% | +$22.5K | ﹤0.01% | 3912 |
|
|
2020
Q3 | $718K | Hold |
6,416
| – | – | ﹤0.01% | 3740 |
|
|
2020
Q2 | $964K | Hold |
6,416
| – | – | ﹤0.01% | 3623 |
|
|
2020
Q1 | $731K | Buy |
6,416
+606
| +10% | +$105K | ﹤0.01% | 3580 |
|
|
2019
Q4 | $1.27M | Hold |
5,810
| – | – | ﹤0.01% | 3574 |
|
|
2019
Q3 | $1.09M | Buy |
5,810
+2,881
| +98% | +$552K | ﹤0.01% | 3631 |
|
|
2019
Q2 | $359K | Buy |
2,929
+937
| +47% | +$199K | ﹤0.01% | 3880 |
|
|
2019
Q1 | $558K | Buy |
1,992
+1,525
| +327% | +$319K | ﹤0.01% | 3750 |
|
|
2018
Q4 | $59K | Hold |
467
| – | – | ﹤0.01% | 4056 |
|
|
2018
Q3 | $91K | Buy |
+467
| New | +$117K | ﹤0.01% | 4086 |
|
|
2017
Q4 | – | Sell |
-120
| Closed | -$41K | – | 4077 |
|
|
2017
Q3 | $41K | Buy |
120
+35
| +41% | +$12.8K | ﹤0.01% | 4038 |
|
|
2017
Q2 | $30K | Hold |
85
| – | – | ﹤0.01% | 4050 |
|
|
2017
Q1 | $46K | Hold |
85
| – | – | ﹤0.01% | 4031 |
|
|
2016
Q4 | $62K | Buy |
85
+2
| +2% | +$2.27K | ﹤0.01% | 4012 |
|
|
2016
Q3 | $127K | Buy |
83
+24
| +41% | +$42.4K | ﹤0.01% | 3958 |
|
|
2016
Q2 | $122K | Buy |
59
+7
| +13% | +$11.7K | ﹤0.01% | 4004 |
|
|
2016
Q1 | $116K | Hold |
52
| – | – | ﹤0.01% | 4016 |
|
|
2015
Q4 | $127K | Buy |
52
+9
| +21% | +$23.4K | ﹤0.01% | 4059 |
|
|
2015
Q3 | $105K | Buy |
43
+27
| +169% | +$112K | ﹤0.01% | 4090 |
|
|
2015
Q2 | $81K | Buy |
+16
| New | +$99.6K | ﹤0.01% | 4130 |
|
Other funds holding RKDA
TRCT
SS
Vanguard Group's RKDA Position: Q4 2025 in Review
Vanguard Group held its Arcadia Biosciences (RKDA) position steady in Q4 2025 at 14,038 shares worth $27.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4292.
Vanguard Group first reported a position in RKDA in Q2 2015 and has held it in 37 quarters since. The position peaked at $2.35M in Q2 2021. 13 funds tracked by Wall St. Rank hold RKDA as of Q4 2025.
- Vanguard Group held 14,038 shares of Arcadia Biosciences worth $27.8K as of Q4 2025.
- Vanguard Group left its Arcadia Biosciences share count unchanged in Q4 2025.
- Arcadia Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4292 holding.
- Vanguard Group first reported a position in Arcadia Biosciences in Q2 2015 and has held it in 37 quarters since.
- Vanguard Group's Arcadia Biosciences position peaked at $2.35M in Q2 2021.
- 13 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.